ERBB4 and cancer: A subset of cancer tissues demonstrates nuclear ErbB4 immunoreactivty [21], [22], and nuclear ErbB4 immunoreactivity is associated with poor clinical outcome compared to membranous or cytoplasmic staining pattern in ErbB4-positive breast cancer [23], [24].